Parasite-derived arginase influences secondary anti-Leishmania immunity by regulating programmed cell death-1-mediated CD4+ T cell exhaustion

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3380-3389

  Mou, Zhirong ^a   Muleme, Helen M ^a   Liu, Dong ^a   Jia, Ping ^a   Okwor, Ifeoma B ^a   Kuriakose, Shiby M ^a   Beverley, Stephen M ^b   Uzonna, Jude E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECONDARY IMMUNE RESPONSE; WILD TYPE;

ANIMALS; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNOLOGIC MEMORY; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84875455887     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202537     Document Type: Article

References (68)

1. Mendonça, M. G., M. E. de Brito, E. H. Rodrigues, V. Bandeira, M. L. Jardim, and F. G. Abath. 2004. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J. Infect. Dis. 189: 1018-1023.
2. Okwor, I., and J. Uzonna. 2008. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 41: 123-136.
3. Scott, P., D. Artis, J. Uzonna, and C. Zaph. 2004. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol. Rev. 201: 318-338.
4. Aebischer, T., S. F. Moody, and E. Handman. 1993. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 61: 220-226.
5. Uzonna, J. E., G. Wei, D. Yurkowski, and P. Bretscher. 2001. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167: 6967-6974.
6. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
7. Carnaúba, D., Jr., C. T. Konishi, V. Petri, I. C. Martinez, L. Shimizu, and V. L. Pereira-Chioccola. 2009. Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: a case report. Int. J. Infect. Dis. 13: e504-e507.
8. Chaudhary, R. G., F. E. Bilimoria, and S. K. Katare. 2008. Diffuse cutaneous leishmaniasis: co-infection with human immunodeficiency virus (HIV). Indian J. Dermatol. Venereol. Leprol. 74: 641-643.
9. Iniesta, V., L. C. Gómez-Nieto, and I. Corraliza. 2001. The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J. Exp. Med. 193: 777-784.
10. Iniesta, V., L. C. Gómez-Nieto, I. Molano, A. Mohedano, J. Carcelén, C. Mirón, C. Alonso, and I. Corraliza. 2002. Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol. 24: 113-118.
11. Kropf, P., J. M. Fuentes, E. Fähnrich, L. Arpa, S. Herath, V. Weber, G. Soler, A. Celada, M. Modolell, and I. Mü ller. 2005. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 19: 1000-1002.
12. Stenger, S., H. Thüring, M. Röllinghoff, and C. Bogdan. 1994. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180: 783-793.
13. Munder, M., K. Eichmann, and M. Modolell. 1998. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J. Immunol. 160: 5347-5354.
14. Modolell, M., I. M. Corraliza, F. Link, G. Soler, and K. Eichmann. 1995. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25: 1101-1104.
15. Munder, M., K. Eichmann, J. M. Morán, F. Centeno, G. Soler, and M. Modolell. 1999. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163: 3771-3777.
16. Corraliza, I. M., G. Soler, K. Eichmann, and M. Modolell. 1995. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem. Biophys. Res. Commun. 206: 667-673.
17. Kropf, P., S. Herath, V. Weber, M. Modolell, and I. Müller. 2003. Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite Immunol. 25: 439-447.
18. Kepka-Lenhart, D., S. K. Mistry, G. Wu, and S. M. Morris, Jr. 2000. Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am. J. Physiol. Regul. Integr. Comp. Physiol. 279: R2237-R2242.
19. Morris, S. M., Jr. 2009. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157: 922-930.
20. Boucher, J. L., J. Custot, S. Vadon, M. Delaforge, M. Lepoivre, J. P. Tenu, A. Yapo, and D. Mansuy. 1994. N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem. Biophys. Res. Commun. 203: 1614-1621.
21. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by Larginine metabolism. Nat. Rev. Immunol. 5: 641-654.
22. Roberts, S. C., M. J. Tancer, M. R. Polinsky, K. M. Gibson, O. Heby, and B. Ullman. 2004. Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania. Characterization of gene deletion mutants. J. Biol. Chem. 279: 23668-23678.
23. da Silva, E. R., T. M. Castilho, F. C. Pioker, C. de Paula Silva, and L. M. Floeter-Winter. 2002. Genomic organization and transcription characterization of the gene encoding Leishmania (Leishmania) amazonensis arginase and its protein structure prediction. Int. J. Parasitol. 32: 727-737.
24. Gaur, U., S. C. Roberts, R. P. Dalvi, I. Corraliza, B. Ullman, and M. E. Wilson. 2007. An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J. Immunol. 179: 8446-8453.
25. Muleme, H. M., R. M. Reguera, A. Berard, R. Azinwi, P. Jia, I. B. Okwor, S. Beverley, and J. E. Uzonna. 2009. Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis. J. Immunol. 183: 8068-8076.
26. Modolell, M., B. S. Choi, R. O. Ryan, M. Hancock, R. G. Titus, T. Abebe, A. Hailu, I. Müller, M. E. Rogers, C. R. Bangham, et al. 2009. Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl. Trop. Dis. 3: e480.
27. Rodriguez, P. C., D. G. Quiceno, and A. C. Ochoa. 2007. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109: 1568-1573.
28. Vercelli, D. 2003. Arginase: marker, effector, or candidate gene for asthma? J. Clin. Invest. 111: 1815-1817.
29. Bruch-Gerharz, D., O. Schnorr, C. Suschek, K. F. Beck, J. Pfeilschifter, T. Ruzicka, and V. Kolb-Bachofen. 2003. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. Am. J. Pathol. 162: 203-211.
30. Zea, A. H., K. S. Culotta, J. Ali, C. Mason, H. J. Park, J. Zabaleta, L. F. Garcia, and A. C. Ochoa. 2006. Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J. Infect. Dis. 194: 1385-1393.
31. Fu, H., A. Khan, D. Coe, S. Zaher, J. G. Chai, P. Kropf, I. Müller, D. F. Larkin, and A. J. George. 2011. Arginine depletion as a mechanism for the immune privilege of corneal allografts. Eur. J. Immunol. 41: 2997-3005.
32. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
33. Butler, N. S., J. Moebius, L. L. Pewe, B. Traore, O. K. Doumbo, L. T. Tygrett, T. J. Waldschmidt, P. D. Crompton, and J. T. Harty. 2012. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13: 188-195.
34. Gigley, J. P., R. Bhadra, and I. A. Khan. 2011. CD8 T Cells and Toxoplasma gondii: A New Paradigm. J. Parasitol. Res. 2011: 243796.
35. Bhadra, R., J. P. Gigley, L. M. Weiss, and I. A. Khan. 2011. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc. Natl. Acad. Sci. USA 108: 9196-9201.
36. Liang, S. C., R. J. Greenwald, Y. E. Latchman, L. Rosas, A. Satoskar, G. J. Freeman, and A. H. Sharpe. 2006. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur. J. Immunol. 36: 58-64.
37. Joshi, T., S. Rodriguez, V. Perovic, I. A. Cockburn, and S. Stäger. 2009. B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5: e1000431.
38. Hernández-Ruiz, J., N. Salaiza-Suazo, G. Carrada, S. Escoto, A. Ruiz-Remigio, Y. Rosenstein, A. Zentella, and I. Becker. 2010. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl. Trop. Dis. 4: e871.
39. Reguera, R. M., R. Balaña-Fouce, M. Showalter, S. Hickerson, and S. M. Beverley. 2009. Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. Mol. Biochem. Parasitol. 165: 48-56.
40. Zaph, C., J. Uzonna, S. M. Beverley, and P. Scott. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10: 1104-1110.
41. Uzonna, J. E., K. L. Joyce, and P. Scott. 2004. Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J. Exp. Med. 199: 1559-1566.
42. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39: 2167-2168.
43. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7: 545-555.
44. Corraliza, I. M., M. L. Campo, G. Soler, and M. Modolell. 1994. Determination of arginase activity in macrophages: a micromethod. J. Immunol. Methods 174: 231-235.
45. DeGrendele, H. C., P. Estess, L. J. Picker, and M. H. Siegelman. 1996. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyteendothelial cell primary adhesion pathway. J. Exp. Med. 183: 1119-1130.
46. DeGrendele, H. C., P. Estess, and M. H. Siegelman. 1997. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278: 672-675.
47. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
48. Smith, P., C. M. Walsh, N. E. Mangan, R. E. Fallon, J. R. Sayers, A. N. McKenzie, and P. G. Fallon. 2004. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J. Immunol. 173: 1240-1248.
49. Jurado, J. O., I. B. Alvarez, V. Pasquinelli, G. J. Martínez, M. F. Quiroga, E. Abbate, R. M. Musella, H. E. Chuluyan, and V. E. García. 2008. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 181: 116-125.
50. Hernández-Ruiz, J., and I. Becker. 2006. [CD8+ cytotoxic lymphocytes in cutaneous leishmaniasis]. Salud Publica Mex. 48: 430-439.
51. Kane, M. M., and D. M. Mosser. 2000. Leishmania parasites and their ploys to disrupt macrophage activation. Curr. Opin. Hematol. 7: 26-31.
52. Carrera, L., R. T. Gazzinelli, R. Badolato, S. Hieny, W. Muller, R. Kuhn, and D. L. Sacks. 1996. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J. Exp. Med. 183: 515-526.
53. Mosser, D. M., and C. L. Karp. 1999. Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Curr. Opin. Immunol. 11: 406-411.
54. Kébaïer, C., J. E. Uzonna, S. M. Beverley, and P. Scott. 2006. Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice. Infect. Immun. 74: 777-780.
55. Okwor, I., S. Kuriakose, and J. Uzonna. 2010. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine 28: 5451-5457.
56. Späth, G. F., L. F. Lye, H. Segawa, D. L. Sacks, S. J. Turco, and S. M. Beverley. 2003. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301: 1241-1243.
57. Uzonna, J. E., G. F. Späth, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172: 3793-3797.
58. Liu, D., C. Kebaier, N. Pakpour, A. A. Capul, S. M. Beverley, P. Scott, and J. E. Uzonna. 2009. Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions. Infect. Immun. 77: 3272-3283.
59. Xu, W., L. Xin, L. Soong, and K. Zhang. 2011. Sphingolipid degradation by Leishmania major is required for its resistance to acidic pH in the mammalian host. Infect. Immun. 79: 3377-3387.
60. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2: 251-262.
61. Kaech, S. M., and E. J. Wherry. 2007. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 27: 393-405.
62. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in Tcell immunity. Curr. Opin. Immunol. 19: 309-314.
63. Sharpe, A. H., E. J.Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
64. Said, E. A., F. P. Dupuy, L. Trautmann, Y. Zhang, Y. Shi, M. El-Far, B. J. Hill, A. Noto, P. Ancuta, Y. Peretz, et al. 2010. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16: 452-459.
65. Meng, Q., P. Yang, B. Li, H. Zhou, X. Huang, L. Zhu, Y. Ren, and A. Kijlstra. 2006. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci. 47: 4444-4452.
66. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166: 1141-1147.
67. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194: 1497-1506.
68. Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170: 5152-5158.